No Data
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Resolved to Nominate Zhang Ruliang as an Executive Director
Trending Industry Today: CHINA VANKE Leads Gains In Top Gainers Yesterday Stocks
Emperor Entertainment Hotel Limited (01541) nominated Mr. Fu Tai-Yat as a non-executive director.
Yiming Angco-B (01541) announced that Mr. Xiaoyong has submitted his resignation as a non-executive director of the company, effective 2024...
Pacific Securities initiated coverage on Immunotech (01541) with a "buy" rating, indicating that the peak sales of its two dual-specificity antibodies are expected to reach 3.17 billion yuan.
King's Financial News | Pacific Securities Research Report indicates that Yimingonc (01541) subsidiary IMM0306 is conducting the Ib/II phase clinical trial: In January 2023, NMPA approved IMM0306 in combination with lenalidomide for Ib/IIa clinical trial application, for front-line treatment of B-cell non-Hodgkin's lymphoma (B-NHL), with the first patient dosed in June 2023. As of June 30, 2024, among 11 evaluable patients, ORR was 90.9%, CR was 27.3%. Currently, the indication for R/RB-NHL is in Phase Ib/II clinical research.
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Subscribe for a Wealth Management Product in Amount of HK$200 Mln From Haitong ASM
China Tong Hong Kong shareholder equity disclosure | September 26th
Hong Kong shareholders' equity disclosure | September 26th
No Data
No Data